TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00433160
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: daily, subcutaneous
Study: NCT01774253
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00075725
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, SC, or IV
Study: NCT00075725
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00075725
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT00075725
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM
Study: NCT00075725
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT00075725
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00075725
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02101684
Drug: Orteronel 300mg BID
Normalized name: Orteronel
DrugBank: Orteronel (DB12066)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03222973
Drug: BIIB033 (opicinumab)
Normalized name: Opicinumab
DrugBank: Opicinumab (DB14959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT01824199
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
Study: NCT00006441
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
Study: NCT00006441
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1250 mg twice daily for 104 weeks.
Study: NCT00006441
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 million units twice daily. Treatment will last until conclusion of study.
Study: NCT00068913
Drug: Dichloroacetate
Normalized name: Dichloroacetate
DrugBank: Dichloroacetic acid (DB08809)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00395135
Drug: Lorcaserin 10 mg BID
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
Study: NCT02684812
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment until aneurysm treatment or maximum dosage of 4 gram
Study: NCT00391469
Drug: Rapid infusion of cold normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03073018
Drug: Fosinopril
Normalized name: Fosinopril
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration, capsules
Study: NCT03073018
Drug: Fosinopril Placebo
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration, capsules
Study: NCT02330302
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
Study: NCT02330302
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
Study: NCT00509860
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 16 mg/m2 by vein Daily Over 1 Hour x 5 Days
Study: NCT00492479
Drug: LubriDerm
Normalized name: Lubriderm
DrugBank: Oxybenzone (DB01428)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00884039
Drug: anecortave acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anterior juxtascleral depot of 15 mg anecortave acetate
Study: NCT00884039
Drug: 30 mg anecortave acetate
Normalized name: acetic acid 30 MG/ML
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anterior juxtascleral depot of 30mg anecortave acetate
Study: NCT00460759
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00460759
Drug: Rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00994734
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: home administration of mifepristone
Study: NCT03884192
Drug: Consolidation Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.
Study: NCT03165123
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
Study: NCT03724981
Drug: Dulaglutide Pen
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Injected on a practice pad.
Study: NCT03724981
Drug: Semaglutide Pen
Normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected on a practice pad.
Study: NCT01773421
Drug: E7820
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8.
Study: NCT01773421
Drug: E7820
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation, the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID.
Study: NCT03511625
Drug: Depo medrol
Normalized name: Depo-Medrol
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depo medrol is an anti-inflammatory glucocorticoid
Study: NCT01360372
Drug: Methylnaltrexone
Normalized name: Methylnaltrexone
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
Study: NCT01360372
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline 0.4 to 0.8 ml injection
Study: NCT00130143
Drug: Ethyol (Amifostine)
Normalized name: amifostine Injection [Ethyol]
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01086956
Drug: epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02358031
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m\^2 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
Study: NCT02358031
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
Study: NCT02358031
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 1000 mg/m\^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
Study: NCT01025349
Drug: Bevacizumab, docetaxel, cisplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks.
Study: NCT02118376
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5ug bid,Subcutaneous injection
Study: NCT03304054
Drug: Amifampridine Phosphate
Normalized name: Amifampridine Phosphate
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
Study: NCT02013206
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib tablets taken orally once daily in the morning.
Study: NCT03040011
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Study: NCT03040011
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Study: NCT03040011
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Study: NCT02727387
Drug: ADM
Normalized name: adMSC
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
Study: NCT02727387
Drug: IFO
Normalized name: Epifoam
DrugBank: Pramocaine (DB09345)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
Study: NCT02727387
Drug: ETO
Normalized name: Ketone
DrugBank: Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone (DB03213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
Study: NCT02968160
Drug: Telmisartan 40mg, 80 mg
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02518958
Drug: RRx-001
Normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02518958
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01301521
Drug: water-soluble cinnamon extract (Cinnulin PF)
Normalized name: WATER SOLUBLE BASE
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
Study: NCT04022785
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC
Study: NCT04022785
Drug: BRD4 Inhibitor PLX51107
Normalized name: Brd4 inhibitor plx51107
DrugBank: PLX51107 (DB17543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00005636
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005636
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03985982
Drug: Botulinum Toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
Study: NCT03223844
Drug: Dextroamphetamine Sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
Study: NCT04098432
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
Study: NCT03165240
Drug: BI 690517
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT04188418
Drug: Fentanyl Citrate Buccal Tablet
Normalized name: fentanyl Buccal Tablet
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given transmucosally
Study: NCT04188418
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01678573
Drug: Treatment A: abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day tablet administered orally on Day 1 of each treatment period.
Study: NCT01678573
Drug: Treatment B: abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day tablets administered orally on Day 1 of each treatment period.
Study: NCT01678573
Drug: Treatment C: abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day tablets administered orally on Day 1 of each treatment period.
Study: NCT01428037
Drug: Misoprostol vaginal Tablet 25 mcg
Normalized name: misoprostol Oral Tablet
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet vaginal insert at 4 hrly interval with maximum of three doses
Study: NCT04446260
Drug: SHR-A1811
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: be administered via intravenous (IV) infusion
Study: NCT00258232
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01981863
Drug: Epsilonaminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
Study: NCT03271879
Drug: Empagliflozin at a dose of 10 mg/day
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
Study: NCT00616811
Drug: vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00616811
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03788018
Drug: lidocaine and dexmedetomidine IV
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
Study: NCT01791881
Drug: Botulinum Toxin Type A(Botox®)
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
Study: NCT03502330
Drug: APX005M
Normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
Study: NCT01344681
Drug: Micafungin sodium
Normalized name: Micafungin Sodium
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~3. Administration Method:~   * Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever.
Study: NCT01344681
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~3. Administration Method:~   * Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever.
Study: NCT03502330
Drug: Cabiralizumab
Normalized name: Cabiralizumab
DrugBank: Cabiralizumab (DB15082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
Study: NCT00801034
Drug: Potassium
Normalized name: Potassium
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, 5 tablets 2 times per day for 28 days
Study: NCT04613557
Drug: Endoxan
Normalized name: Endoxana
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preconditioning chemotherapy
Study: NCT04613557
Drug: Fludara
Normalized name: Fludara
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconditioning chemotherapy
Study: NCT00132691
Drug: fluocinolone acetonide intraocular implant
Normalized name: fluocinolone acetonide Drug Implant
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
Study: NCT00132691
Drug: oral corticosteroid with immunosuppressive agents as needed
Normalized name: Primatene with ephedrine Oral Product
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone
Study: NCT03502330
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
Study: NCT02715024
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02715024
Drug: Solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02726022
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As per treating physician discretion and according to summary of product characteristics.
Study: NCT02726022
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As per treating physician discretion and according to summary of product characteristics.
Study: NCT01466660
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: afatinib once daily
Study: NCT01466660
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib once daily
Study: NCT00309712
Drug: fenofibrate 160 mg and placebo
Normalized name: fenofibrate 160 MG
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04092894
Drug: Suvorexant 20 mg
Normalized name: suvorexant 20 MG
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of oral Suvorexant 20 mg
Study: NCT02743949
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan over-encapsulated capsules
Study: NCT02743949
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole over-encapsulated tablets
Study: NCT02743949
Drug: Esomeprazole Placebo
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole placebo-matching capsules
Study: NCT01404793
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
Study: NCT00198393
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg/day, until progression
Study: NCT00198393
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m² D1 and D8 (D1=D28, until progression)